Staidson Beijing Biopharma (300204) — Net Asset Quality Index
Staidson Beijing Biopharma (300204) has a Net Asset Quality Index of 62.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.28 Billion minus total liabilities of CN¥486.07 Million yields net assets of CN¥794.92 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 300204 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Staidson Beijing Biopharma Net Asset Quality Index Over Time (2007–2025)
This chart shows how Staidson Beijing Biopharma's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 62.1%, representing net assets of CN¥794.92 Million against total assets of CN¥1.28 Billion CNY. See Staidson Beijing Biopharma working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Staidson Beijing Biopharma (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Staidson Beijing Biopharma.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 63.7% | CN¥806.72 Million | CN¥1.27 Billion | CN¥459.48 Million | ▼ -16.0 pp |
| 2024 | 79.7% | CN¥916.76 Million | CN¥1.15 Billion | CN¥232.85 Million | ▲ +3.1 pp |
| 2023 | 76.6% | CN¥1.02 Billion | CN¥1.33 Billion | CN¥311.55 Million | ▼ -4.5 pp |
| 2022 | 81.1% | CN¥1.35 Billion | CN¥1.67 Billion | CN¥315.45 Million | ▼ -3.8 pp |
| 2021 | 84.9% | CN¥1.55 Billion | CN¥1.83 Billion | CN¥276.25 Million | ▼ -0.6 pp |
| 2020 | 85.5% | CN¥1.59 Billion | CN¥1.86 Billion | CN¥268.70 Million | ▼ -2.3 pp |
| 2019 | 87.8% | CN¥1.64 Billion | CN¥1.86 Billion | CN¥227.18 Million | ▼ -0.9 pp |
| 2018 | 88.7% | CN¥2.46 Billion | CN¥2.77 Billion | CN¥314.30 Million | ▲ +4.6 pp |
| 2017 | 84.1% | CN¥2.21 Billion | CN¥2.63 Billion | CN¥419.14 Million | ▲ +2.4 pp |
| 2016 | 81.6% | CN¥1.92 Billion | CN¥2.35 Billion | CN¥432.32 Million | ▲ +0.3 pp |
| 2015 | 81.3% | CN¥1.68 Billion | CN¥2.07 Billion | CN¥387.06 Million | ▼ -2.3 pp |
| 2014 | 83.6% | CN¥1.51 Billion | CN¥1.81 Billion | CN¥297.54 Million | ▼ -0.1 pp |
| 2013 | 83.7% | CN¥1.31 Billion | CN¥1.57 Billion | CN¥255.47 Million | ▼ -2.9 pp |
| 2012 | 86.6% | CN¥1.24 Billion | CN¥1.43 Billion | CN¥192.15 Million | ▼ -9.3 pp |
| 2011 | 95.9% | CN¥1.10 Billion | CN¥1.15 Billion | CN¥47.32 Million | ▲ +33.1 pp |
| 2010 | 62.8% | CN¥166.23 Million | CN¥264.88 Million | CN¥98.66 Million | ▼ -17.7 pp |
| 2009 | 80.5% | CN¥119.72 Million | CN¥148.75 Million | CN¥29.03 Million | ▲ +12.3 pp |
| 2008 | 68.2% | CN¥62.82 Million | CN¥92.07 Million | CN¥29.25 Million | ▲ +27.0 pp |
| 2007 | 41.2% | CN¥33.87 Million | CN¥82.22 Million | CN¥48.35 Million | — |